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Abstract
Background: Optune™, previously known as the NovoTTF-100A System™, generates Tumor Treating Fields (TTFields),
an effective anti-mitotic therapy for glioblastoma. The system delivers intermediate frequency, alternating electric fields
to the supratentorial brain. Patient therapy is personalized by configuring transducer array layout placement on the
scalp to the tumor site using MRI measurements and the NovoTAL System. Transducer array layout mapping optimizes
therapy by maximizing electric field intensity to the tumor site. This study evaluated physician performance in
conducting transducer array layout mapping using the NovoTAL System compared with mapping performed by the
Novocure in-house clinical team.
Methods: Fourteen physicians (7 neuro-oncologists, 4 medical oncologists, and 3 neurosurgeons) evaluated five
blinded cases of recurrent glioblastoma and performed head size and tumor location measurements using a standard
Digital Imaging and Communications in Medicine reader. Concordance with Novocure measurement and intra- and
inter-rater reliability were assessed using relevant correlation coefficients. The study criterion for success was a
concordance correlation coefficient (CCC) >0.80.
Results: CCC for each physician versus Novocure on 20 MRI measurements was 0.96 (standard deviation, SD ± 0.03,
range 0.90–1.00), indicating very high agreement between the two groups. Intra- and inter-rater reliability correlation
coefficients were similarly high: 0.83 (SD ±0.15, range 0.54–1.00) and 0.80 (SD ±0.18, range 0.48–1.00), respectively.
Conclusions: This user study demonstrated an excellent level of concordance between prescribing physicians and
Novocure in-house clinical teams in performing transducer array layout planning. Intra-rater reliability was very high,
indicating reproducible performance. Physicians prescribing TTFields, when trained on the NovoTAL System, can
independently perform transducer array layout mapping required for the initiation and maintenance of patients on
TTFields therapy.
Keywords: Glioblastoma, Optune, NovoTAL System, NovoTTF-100A System, Tumor Treating Fields, TTFields
* Correspondence: achaudhry@novocure.com
1Medical Affairs, Novocure Ltd., New York, NY, USA
Full list of author information is available at the end of the article
WORLD JOURNAL OF 
SURGICAL ONCOLOGY
© 2015 Chaudhry et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chaudhry et al. World Journal of Surgical Oncology  (2015) 13:316 
DOI 10.1186/s12957-015-0722-3
Background
NovoTTF-100A System (Optune™, Novocure Ltd., Haifa,
Israel) is a unique modality of anti-cancer therapy deliv-
ering specifically tuned alternating electric fields, Tumor
Treating Fields (TTFields), and is approved by the US
Food and Drug Administration (FDA) for the treatment
of patients with glioblastoma multiforme (GBM). Initial
approval was based on the results of a large, random-
ized, phase 3 study demonstrating comparable efficacy
and favorable safety as monotherapy, compared with the
best physician’s choice of active chemotherapy in pa-
tients with recurrent GBM [1]. TTFields evolved from
preclinical observations that alternating electric fields
could selectively arrest cellular division in cancer cells
by impairing normal mitosis and cytokinesis. The effects
of TTFields, which have been described previously, in-
clude interference with normal mitotic spindle assembly
during metaphase, cellular membrane disruption, cyto-
plasmic blebbing during anaphase, aberrant chromo-
somal segregation, and intracellular dielectrophoresis of
polar macromolecules, leading to the destruction of the
cleavage furrow, during cytokinesis [2–4]. As the ef-
fects of TTFields are selective for dividing cells, quies-
cent cells in the normal human brain are spared.
TTFields possess directional specificity, frequency de-
pendence, and intensity dependence in exerting a thera-
peutic effect across different cell lines. In glioma cells,
maximal inhibition of cellular proliferation was observed
at a frequency of 200 kilohertz (kHz), and this effect in-
creased with higher electric field intensities [2].
Complete arrest of cellular proliferation in cultures oc-
curred when electric field intensity reached 2.25 volts
per centimeter (V/cm). In addition, the effect of
TTFields is directly proportional to the orientation of
the mitotic axis relative to electric field direction. Cellu-
lar damage is maximal when the axis of division is
aligned with the direction of the electric field and is
minimal when the cleavage axis is orthogonal to the field
direction [2]. By applying electric fields in multiple direc-
tions, an additive cytotoxic effect can be obtained [3]. To
characterize how electric fields behave and distribute
within the human head, modeling frameworks based on
anatomical head models using Finite Element Method
(FEM) simulations have been developed [5]. These simula-
tions yield realistic head models based on magnetic reson-
ance imaging (MRI) measurements and compartmentalize
tissue types such as skull, white matter, gray matter, and
cerebrospinal fluid (CSF) within the head. Each tissue type
is assigned dielectric properties for relative conductivity
and permittivity, and simulations are run whereby differ-
ent transducer array configurations are applied to the sur-
face of the model in order to understand how an
externally applied electric field, of preset frequency, will
distribute throughout the brain. The results of these
simulations, employing paired array configurations, a con-
stant current, and a preset frequency of 200 kHz, have
demonstrated that electric field distributions are relatively
nonuniform throughout the brain and that electric field
intensities exceeding 1 V/cm are generated in most tissue
compartments except CSF [5]. These results are obtained
assuming total currents with a peak-to-peak value of
1800 milliamperes (mA) at the transducer array-scalp
interface. This threshold of electric field intensity is suffi-
cient to arrest cellular proliferation in glioblastoma cell
lines. Additionally, by manipulating the configuration of
paired arrays, it is possible to achieve an almost tripling of
electric field intensity to a particular region of the brain
(Fig. 1). The NovoTAL™ System (Novocure Ltd., Haifa,
Israel) is used to guide the optimal transducer array layout
for a patient based on the location and extent of their
contrast-enhancing tumor. Initial morphometric head size
measurements are determined from the T1 sequences of a
brain MRI, using axial and coronal views. Postcontrast
axial and coronal MRI slices are selected to demonstrate
the maximal diameter of enhancing lesions. Employing
measures of head size and distances from predetermined
fiducial markers to tumor margins, the system runs per-
mutations and combinations of paired array layouts in
order to generate the configuration which delivers max-
imal electric field intensity to the tumor site. The output
is a three-dimensional array layout map, which is used by
the patient and caregiver in arranging arrays on the scalp
during the normal course of TTFields therapy (Fig. 2).
This user study aimed to assess TTFields certified pre-
scribing physician competency in autonomously perform-
ing the standard measurements required for initiating and
maintaining patients on optimal therapy.
Fig. 1 Electric field magnitude and distribution (in V/cm) shown in
coronal view from a finite element method simulation model. This
simulation employs a left-right paired transducer array configuration.
Reprinted with permission from Miranda et al. [5]
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Methods
In January 2013, 14 physicians (7 neuro-oncologists, 4 med-
ical oncologists, and 3 neurosurgeons) were randomly se-
lected from the pool of NovoTTF-100A System certified
prescribing sites. All physicians provided written informed
consent to participate in the study. The participants repre-
sented approximately 20 % of certified sites at the time of
this study. The physicians were representative of the
TTFields therapy certified prescriber base and covered the
core specialties that may be involved in standard GBM
treatment planning.
Each physician had to complete mapping measure-
ments on a total of five distinct MRI cases. The MRI
measurements were obtained using the same standard
Digital Imaging and Communications in Medicine
(DICOM) viewer (MicroDicom). The MRIs were
anonymized to protect patient privacy and included
scans with the following anatomical lesions: a right
fronto-temporal tumor, a right parieto-temporal
tumor, a left fronto-temporal tumor, a left parieto-
occipital tumor, and a multi-focal midline tumor. Test
case MRIs were randomly selected from a pool of
scans featuring tumors in the same anatomical loca-
tions. A standardized NovoTAL measurement case re-
port form was provided outlining the required
measurements to be obtained for each case. All mea-
surements commenced from fiducial markers at the
outer margin of the scalp and extended tangentially
from a right-, anterior-, superior origin.
Firstly, morphometric head size was estimated from
the axial T1 MRI sequence selecting the most apical
image which still included the orbits (or the image dir-
ectly above the superior edge of the orbits) (Fig. 3a).
A total of 20 measurements were required to map
each distinct case:
1. Maximal antero-posterior (A-P) head size, commencing
measurement from the outer margin of the scalp.
2. Maximal width of the head perpendicular to the A-P
measurement: right to left lateral distance.
3. Distance from the far most right margin of the scalp
to the anatomical midline.
Coronal view head size measurements were ob-
tained on the T1 MRI sequence selecting the image
at the level of the ear canal (Fig. 3b).
The following coronal head size measurements were
obtained:
4. A vertical measurement from the apex of the scalp
to an orthogonal line delineating the inferior margin
of the temporal lobes.
5. Maximal right to left lateral head width.
6. Distance from the far right margin of the scalp to
the anatomical midline.
Measurements for tumor location were made in the
following manner using T1 postcontrast MRI sequences,
firstly on the axial image demonstrating maximal enhan-
cing tumor diameter (Fig. 3c):
7. The maximal A-P head size, excluding the nose.
8. The maximal right to left lateral diameter, measured
perpendicular to the A-P distance.
9. Distance from the right margin of the scalp to the
anatomical midline.
10.Distance from the right margin of the scalp to the
closest tumor margin, measured parallel to the
right-left lateral distance and perpendicular to the
A-P measurement.
11.Distance from the right margin of the scalp to the
farthest tumor margin, measured parallel to the
right-left lateral distance, perpendicular to the A-P
measurement.
12.Distance from the front of the head, measured
parallel to the A-P measurement, to the closest
tumor margin.
13.Distance from the front of the head, measured
parallel to the A-P measurement, to the farthest
tumor margin.
Coronal view tumor measurements were completed
identifying the postcontrast T1 MRI slice featuring
Fig. 2 Sample transducer array layout map guiding placement of
transducer arrays on the scalp
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the maximal diameter of tumor enhancement
(Fig. 3d).
14.The maximal distance from the apex of the scalp to
the inferior margin of the cerebrum. In anterior
slices, this would be demarcated by a horizontal line
drawn at the inferior margin of the frontal or
temporal lobes, and posteriorly, it would extend to
the lowest level of visible tentorium.
15.Maximal right to left lateral head width.
16.Distance from the right margin of the scalp to the
anatomical midline.
17.Distance from the right margin of the scalp to the
closest tumor margin, measured parallel to the
right-left lateral distance.
18.Distance from the right margin of the scalp to the
farthest tumor margin, measured parallel to the
right-left lateral distance.
19.Distance from the apex of the head to the closest
tumor margin, measured parallel to the superior
apex to inferior cerebrum line.
20.Distance from the apex of the head to the farthest
tumor margin, measured parallel to the superior
apex to inferior cerebrum line.
All measurements were rounded to the nearest milli-
meter and were entered into the NovoTAL case report
form and software for analysis. Gold standard measure-
ments performed by Novocure in-house clinical staff
were collected for all five cases and were used as the
comparator benchmark.
Statistical analysis
Degree of agreement between user study participants
and Novocure gold standard measurements were
assessed for each individual physician and for each indi-
vidual case using the concordance correlation coefficient
(CCC) method using the Statistical Analysis System
(SAS) version 9.3 software. Intragroup and intergroup
agreement was assessed using the Shourt and Fliess’
intra-rater (ICC(3,1)) and inter-rater (ICC(2,1)) concord-
ance correlation methods [6]. Overall, for the user study
to be positive on the primary analysis, the average
Fig. 3 Magnetic resonance imaging. a Axial T1 sequence slice containing most apical image, including orbits used to measure head size. b Coronal T1
sequence slice selecting image at level of ear canal used to measure head size. c Postcontrast T1 axial image shows maximal enhancing tumor diameter
used to measure tumor location. d Postcontrast T1 coronal image shows maximal enhancing tumor diameter used to measure tumor location
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physician-company agreement required a CCC >0.80,
performed with an accuracy threshold of ±7.5 mm. This
threshold represents approximately 0.001 % of the wave-
length of 200 kHz TTFields. For the secondary analyses,
intragroup agreement, ICC(3,1), and intergroup agree-
ment, ICC(2,1), values >0.80 would indicate near perfect
concordance, and values in the range of 0.61–0.80 would
indicate substantial agreement.
Results
Data were collected from all 14 user study participants
in January 2013. All physicians obtained the 20 required
measurements for each of the five distinct MRI cases,
and there were no missing data. Pairwise concordance
between the study participants and Novocure gold
standard measurements was assessed for each physician
case (Fig. 4). CCC was calculated for each physician ver-
sus gold standard measures on 20 unique data points
and then averaged. The average CCC was 0.88 (SD 0.11).
Using the predetermined threshold of ±7.5 mm for each
of the 20 measurements, the average physician agree-
ment with gold standard was 0.96 (SD 0.03, range
0.90–1.00). Therefore, the study was positive for the pri-
mary analysis (Table 1). The intra-rater reliability for the
14 physicians across the five individual MRI cases was
assessed using the intraclass correlation coefficient
ICC(2,1). The 20 measurement points from each MRI
case were averaged to perform the calculation, demon-
strating an average ICC(3,1) of 0.80 (SD 0.18, range
0.48–1.00), thus showing excellent intra-rater reliability
in performing the key measurements required for
TTFields therapy planning. The inter-rater reliability
ICC(2,1) was similarly high, at 0.80.
Discussion
The results of this user study have demonstrated for the
first time that irrespective of clinical specialty, physicians
prescribing TTFields for patients with GBM can inde-
pendently perform the measurements required for treat-
ment initiation and maintenance with the same degree of
accuracy as gold standard mapping and planning cur-
rently performed by Novocure clinicians. The concord-
ance between in-house clinicians and study participants

























































































































Fig. 4 Scatterplots and linear correlation between Novocure and physician magnetic resonance imaging (MRI) measurement for MRI cases 1 to 5.
Error bars represent ±7.5 mm from Novocure measurements. Each color represents a set of measurements made by a different physician (n = 14).
Mean (SD) R2 linear correlations for all physicians versus Novocure were a case 1, 0.9966 (0.0039); b case 2, 0.9954 (0.0041); c case 3, 0.9967
(0.0050); d case 4, 0.9963 (0.0037); and e case 5, 0.9935 (0.0066)
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positive results of this user study led to the submission of
a supplement to the premarket approval application
(PMA) being approved by the FDA in August 2013. The
PMA supplement approval provided authorization for
transferring the responsibility for performing NovoTAL
transducer array mapping from Novocure to trained phy-
sicians prescribing TTFields. Until recently, all personal-
ized transducer array layout maps, which are prerequisite
for treatment initiation with TTFields, were generated by
Novocure in-house clinical staff. However, there are
many clinical advantages in transferring the process of
array layout mapping to the prescribing physician. The
prescribing physician can better correlate radiographic
findings with a patient’s clinical status and at their own
discretion, better evaluate which specific areas of enhan-
cing lesion to focus the TTFields toward. Since the recent
inclusion of TTFields to the clinical armamentarium is
for patients with newly diagnosed aswell as recurrent
GBM, reports are emerging in the literature that describe
“out of field” tumor recurrences that subsequently re-
spond to therapy following adjustment of the transducer
array configuration, based on evidence of radiographic
recurrence [7]. In one case, a 41-year-old man who
underwent gross total resection for a left frontal GBM
with primitive neuroectodermal (PNET) component sub-
sequently received standard adjuvant radiochemotherapy
followed by a combination of TTFields with metronomic
temozolomide. At 6 months, a new distal lesion was
noted in the left parietal lobe. Following a further resec-
tion, readjustment of the transducer array configuration
to target the distal parietal lesion, and a change to his
chemotherapy regimen, the patient was able to continue
on TTFields therapy for more than a year. Cases such as
these suggest that local tumor progression may respond
to adjustment of TTFields when there are imaging
changes.
Interpreting radiographic changes in response to GBM
therapy can be complicated by the use of agents that im-
pact the blood brain barrier, impeding uptake of con-
trast, such as anti-angiogenic therapy [8–10]. As
prescribing clinicians have comprehensive information
on a patient’s clinical history and prior therapies received
in the course of their GBM management, they are better
placed to interpret which MRI features are likely to rep-
resent true active tumor, a clinical response, pseudo-
response, stable disease, or frank progression over a
series of scans. This may lead to a more informed ap-
proach when planning TTFields treatment and may ul-
timately help improve patient outcomes.
Conclusions
This user study demonstrated a very high degree of con-
cordance between prescribing physicians and the in-
house Novocure clinical team in performing transducer
array layout planning for patients with recurrent GBM.
Intra-rater reliability was very high, indicating that phys-
ician performance was reproducible. Physicians prescrib-
ing the TTFields, when trained on the NovoTAL System,
should be able to independently perform transducer
array layout mapping required for the initiation and
maintenance of patients receiving TTFields. Adjusting
the configuration of transducer arrays in response to
changes in a patient’s imaging may impact clinical out-
comes. Prospective studies are warranted to determine
the optimal timing at which a new transducer array lay-
out map should be generated for patients receiving on-
going therapy with TTFields.
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Table 1 Summary of average concordance correlation
coefficient between Novocure and physicians for MRI test cases
by tumor position
Test case Tumor position Average concordance
correlation coefficient (CCC) R2 ± SD
1 Right fronto-temporal 0.9966 ± 0.0039
2 Right parieto-occipital 0.9954 ± 0.0041
3 Left fronto-temporal 0.9967± 0.0050
4 Left parieto-occipital 0.9963 ± 0.0037
5 Midline, multi-focal 0.9935 ± 0.0066
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